Tanja Obradovic: PIONeeR Project results will be presented at ESMO 2024 Presidential Symposium
Tanja Obradovic shared on LinkedIn:
“Just announced that exciting results will be presented at ESMO 2024 Presidential Symposium from PIONeeR Project (Precision Immuno-Oncology for advanced Non-Small Cell Lung Cancer Patients with PD-(L)1 ICI Resistance) -Presentation Number: LBA8, Presidential Symposium III: Eyes to the future.
PIONeeR is a major international hospital-university research project addressing the critical challenge of resistance to PD-1(L1) immune checkpoint inhibitors (ICIs) in over 450 patients with advanced non-small cell lung cancer (NSCLC), including a biomarker program (> 400 biomarkers).
Trial (NCT03493581) is evaluating responses in patients who had either first or latter lines PD(L)1 inhibitor mono therapy or chemo combo combination and developed resistance.”
Source: Tanja Obradovic/LinkedIn
Other posts featuring tanja Obradovic on oncodaily.com
Tanja Obradovic is the Vice President of Oncology Scientific Affairs at ICON PLCh. She has over 20 years of clinical research experience and has led major pharmaceutical companies for 13 years. Her research focuses on small molecules, antibodies, cell and gene therapy, and major immunotherapy of PD1 inhibitors.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023